Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms.
Explore this paper's citation graph
Summary
It is concluded that abbreviating methotrexate prophylaxis or infusing donor buffy-coat cells increased the incidence of acute GVHD and related mortality without alteringThe incidence of chronic GV HD or the recurrence of malignant disease.
- Type
- article
- Published
- 1989-03-30
- Cited by
- 358
- References
- 48
- OpenAlex
- https://openalex.org/W1992401639
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:12469982
Keywords
Medicine, Methotrexate, Total body irradiation, Leukemia, Internal medicine
References
- Bone-marrow transplantation (first of two parts).
- Treatment of established human graft-versus-host disease by antithymocyte globulin.
- Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation.
- One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation.
- Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.
- Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.
- Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma.
- Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression.
- Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.
- Adoptive immunotherapy of acute leukemia: experimental and clinical results.
- Regimen-related toxicity in patients undergoing bone marrow transplantation.
- Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.
- Uniformity and standardization of single and opposing cobalt 60 sources for total body irradiation.
- Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors.
- Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone.
- Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity
- ADOPTIVE CHEMOIMMUNOTHERAPY OF CANCER IN ANIMALS: A REVIEW OF RESULTS, PRINCIPLES, AND PROBLEMS *
- Acute and chronic graft-versus-host disease in man.
- Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow
- Efficacy of a short course (four doses) of methotrexate following bone marrow transplantation for prevention of graft-versus-host disease.
Cited by
- Bone marrow transplantation for acute non-lymphoblastic leukemia.
- Adoptive immunotherapy with haploidentical allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation.
- Development of a sample bank and clinical database for the retrospective analysis of unrelated bone marrow transplants : a pilot study of 138 transplants using RSCA for high resolution HLA matching
- Non-Hodgkin’s Lymphoma
- Immune therapy of chronic myelogenous leukemia.
- Allogeneic Intrabone Marrow‐Bone Marrow Transplantation plus Donor Lymphocyte Infusion Suppresses Growth of Colon Cancer Cells Implanted in Skin and Liver of Rats
- Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.
- Supportive care of the marrow transplant recipient: the Seattle Experience.
- Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy.
- Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.
- Bone marrow transplantation for acute nonlymphocytic leukemia (ANL).
- Cellular adoptive immunotherapy after bone marrow transplantation.
- The role of immunotherapy in the treatment of acute myeloblastic leukemia: from allogeneic bone marrow transplantation to the application of interleukin 2.
- Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy.
- Non myeloablative "mini transplants".
- Transplantation of allogeneic CD34+ blood cells.
- Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
- Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions.
- Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
- Facultat de Medicina
Related papers
- Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate
- Efficacy of high-dose cyclophosphamide in combination with total-body irradiation in the treatment of acute myelocytic leukemia: studies in a relevant rat model.
- The Use of Cyclophosphamide, Methotrexate, and 5‐Fluorouracil in the Treatment of Merkel Cell Carcinoma
- Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF) in advanced breast cancer
- Adjuvant chemotherapy with six drugs (adriamycin, methotrexate, cisplatinum, bleomycin, cyclophosphamide and dactinomycin) for non-metastatic high grade osteosarcoma of the extremities. Results of 32 patients and comparison to 127 patients concomitantly treated with the same drugs in a neoadjuvant f
- Combined immunosuppression using cyclophosphamide plus total lymphoid irradiation in preparation for allogeneic marrow transplantation in humans.
- Non-Myeloablative Conditioning with Low-Dose Total Body Irradiation in Place of Cyclophosphamide Induces Mixed Chimerism and Long-Term Immunosuppression Free Allograft Survival without Acute Kidney Injury in HLA Mismatched Kidney Transplantation
- TREATMENT OF CANINE GRAFT-VERSUS-HOST DISEASE WITH METHOTREXATE AND CYCLOPHOSPHAMIDE FOLLOWING BONE MARROW TRANSPLANTATION FROM HISTOINCOMPATIBLE DONORS